Genentech
A Member of the Roche Group

2025 Independent Medical Education Request for Proposals

Issue Date: **June 6, 2025**

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposals (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	• U.S. based education provider • Registered account in gFRS • Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	• Educational initiatives must be U.S.-based only

Genentech
A Member of the Roche Group

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 10 weeks to complete a **full grant proposal** through funding.gene.com. When submitting the application, please be sure to: ● Select the Therapeutic Area (Oncology), and Disease State (**Colorectal Cancer**) ● Include "RFP June 2025 [Insert Program Title]" in the program title of the grant	August 15, 2025
Step 2	Grant decisions will be made by Genentech by August 29, 2025 and decision notifications will be issued to the accredited educational provider through gFRS.	August 29, 2025
Step 3	If your grant is approved, one activity within the program must launch before October 27, 2025.	October 27, 2025

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Genentech
A Member of the Roche Group

Currently Available RFP Focus Area:

Focus	Opportunity
Therapeutic Area: Oncology **Disease Areas:** Colorectal Cancer **Primary Learning Audiences:** Community Cancer Teams Community Oncologists Gastrointestinal Surgeons Pathologists Gastroenterologists **Support Available:** Up to $350,000	Precision medicine approaches are increasingly vital in the clinical management of early stage colorectal cancer (CRC). While deficient mismatch repair (dMMR) protein expression and microsatellite instability-high (MSI-H) are distinct biomarkers, they both indicate a dysfunctional DNA mismatch repair system, a fundamental biological phenomenon in CRC. Many community healthcare providers may be unaware of the conceptual and practical equivalence between dMMR and MSI-H testing approaches, which can lead to misinterpretation of test results and interfere with therapeutic decisions. Genentech is seeking proposals for education that foster a deeper understanding of MMR/MSI testing concordance and the expanding actionability of these biomarkers with checkpoint inhibitors to optimize patient care and facilitate timely access to personalized therapies in early stage CRC. **References:** 1. Ali-Fehmi, R., Krause, H.B., Morris, R.T., Wallillich, J.J., Corey, L, Bandyopadyay, S., Kheil, M., Elbashir, L, Zaiem, F., Quddus, M.R., Abada, E., Herzog, T., Karnezis, A.N., Antonarakis, E.S., Kasi, P.M., Wei, S., Swensen, J., Elliott, A., Xiu, J., Hechtman, J., Spetzler, D., Abraham, J., Radovich, M., Sledge, G., Oberley, M.J., & Bryant, D. (2024) Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in > 28,000 colorectal tumors. [Poster Presentation]. *Journal of Clinical Oncology, Precision Oncology*, *8(Oct 2024)*. https://doi.org/10.1200/PO.23.00648 2. Cervantes B, André T, Cohen R. Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231170473 3. Romain Cohen et al. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. JCO 39, 642-651(2021). doi:10.1200/JCO.20.01600